# Bausch Health Companies Inc.

> Bausch Health is a Laval-based global pharmaceutical group built around specialty medicines, consumer health products and medical devices. Its portfolio spans Salix gastrointestinal drugs, Solta aesthetics systems, OraPharma dental products, dermatology and neurology brands, international generics, and a controlling interest in Bausch + Lomb. The practical story is a trade-off: Bausch owns products with real clinical and commercial staying power, but its acquisition-era debt, dependence on Xifaxan and looming pricing and patent pressure keep the company in a permanent race between cash generation and the calendar.

- **Founded:** 1959
- **Headquarters:** Laval, Canada
- **Founders:** Milan Panić (Founder of ICN Pharmaceuticals, a predecessor company), Eugene Melnyk (Founder of Biovail, the Canadian predecessor that merged with Valeant)
- **Team size:** Approximately 20,300 employees at December 31, 2025, including about 13,000 at Bausch + Lomb; Bausch Health excluding Bausch + Lomb describes a global team of more than 7,000.
- **Products:** Xifaxan, Relistor, Trulance, Jublia, Cabtreo
- **Notable:** $10.266 billion of consolidated revenue in 2025, up 7% year over year., Xifaxan revenue reached $2.212 billion in 2025., Approximately 1,000 products across five reportable segments in 2025.

## Products & services

- **Xifaxan** — Rifaximin tablets used for approved gastrointestinal and liver-related indications, including reducing recurrence risk of overt hepatic encephalopathy and treating IBS-D in adults.
- **Relistor** — Methylnaltrexone for opioid-induced constipation in specified adult patient populations.
- **Trulance** — Once-daily plecanatide tablets for adults with chronic idiopathic constipation or IBS-C.
- **Jublia** — Topical efinaconazole solution for onychomycosis of the toenails.
- **Cabtreo** — A fixed-dose topical acne treatment combining clindamycin phosphate, adapalene and benzoyl peroxide.
- **Arestin** — Minocycline microspheres administered in periodontal pockets as an adjunct to scaling and root planing.
- **Thermage FLX** — A Solta Medical radiofrequency system used by qualified providers for non-invasive aesthetic treatments.
- **Clear + Brilliant Touch** — A Solta Medical laser platform for skin resurfacing treatments, launched in Canada in 2026.
- **International pharmaceuticals** — A broad portfolio of branded, generic and branded-generic medicines and OTC products sold outside the United States.
- **Bausch + Lomb portfolio** — Vision-care, surgical, pharmaceutical and consumer eye-health products sold through Bausch Health's controlling interest in the separately listed company.

## Achievements

- $10.266 billion of consolidated revenue in 2025, up 7% year over year.
- Xifaxan revenue reached $2.212 billion in 2025.
- Approximately 1,000 products across five reportable segments in 2025.
- Thirteen consecutive quarters of year-over-year revenue growth for Bausch Health excluding Bausch + Lomb by the second quarter of 2026.
- Second-quarter 2026 consolidated revenue rose 13% to $2.85 billion; the company raised full-year guidance.
- Completed $9.6 billion of refinancing activity during 2025 and reduced net debt by $376 million for the year.
- Solta Medical reported more than five million Thermage treatments by September 2025.
- OraPharma's Arestin reached its 25th anniversary in 2026.
- The 2026 Salix GI Health Scholars program awarded ten $10,000 scholarships for its seventh year.

## Latest updates

- **2026-08** — CEO Thomas J. Appio joined the Bausch + Lomb board, and Salix announced the 2026 GI Health Scholars winners.
- **2026-07** — Reported second-quarter consolidated revenue of $2.85 billion, up 13%, and raised 2026 guidance.
- **2026-07** — Québec became the first Canadian province to list OKEDI on its public formulary; Alberta added reimbursement for eligible Elidel patients.
- **2026-02** — Solta Medical launched Clear + Brilliant Touch in Canada; OraPharma marked 25 years of Arestin.
- **2026-01** — Both RED-C Phase 3 trials were safe and well tolerated but did not achieve their primary endpoint.
- **2025-12** — Solta Medical acquired longtime China distribution partner Shibo Group and Bausch Health completed a $1.7 billion debt exchange offer.
- **2025-09** — Completed the DURECT acquisition for $84 million of total consideration, adding larsucosterol, an investigational treatment for alcohol-associated hepatitis.

## Links

- Website: https://www.bauschhealth.com/
- LinkedIn: https://www.linkedin.com/company/bausch-health-companies/
- Twitter/X: https://twitter.com/bauschhealth
- Facebook: https://facebook.com/BauschHealthCA/

---

Profile page: https://yespress.io/bausch-health-companies-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-23